Glenmark Life Sciences IPO price band, GMP, Allotment, Listing date and Price

Glenmark Life Sciences IPO details (27 – 29 July), (Price: 695-720)

Glenmark Life Sciences IPO price band, GMP, Allotment, Listing date and Price
Glenmark Life Sciences IPO price band, GMP, Allotment, Listing date and Price

Listing date and Listing Price of Glenmark Life Sciences IPO:

  1. Glenmark Life Sciences IPO listed on BSE and NSE exchanges on – Click Here
  2. Listing Price of Glenmark Life Sciences IPO on NSE – Click Here
  3. Listing Price of Glenmark Life Sciences IPO on BSE – Click Here

Grey Market premium (GMP) price of Glenmark Life Sciences IPO :

Grey Market premium (GMP) price of Glenmark Life Sciences IPO is Rs 250. Grey Market premium (GMP) of Glenmark Life Sciences IPO means, unofficially if someone buys or sells his application at a fixed rate irrespective of listing price. (Source : ipowatch.in) Check latest GMP of all IPOs.

Glenmark Life Sciences IPO Allotment link status on Kfintech:

Check the allotment status of Glenmark Life Sciences IPO on these three links given by Kfintech.

  1. Glenmark Life Sciences IPO Allotment Link 1 – https://kosmic.kfintech.com/ipostatus/
  2. Glenmark Life Sciences IPO Allotment Link 2 – https://kcas.kfintech.com/ipostatus/
  3. Glenmark Life Sciences IPO Allotment Link 3 -https://evault.kfintech.com/ipostatus/

Glenmark Life Sciences IPO Allotment link status on Kfintech can be checked by Application No or DPID/Client ID or PAN and enter ‘Captcha’.

Glenmark Life Sciences IPO Allotment link status on Kprism app:

KPRISM, an app by KFin Technologies Pvt Ltd (Registrar of this IPO) can be downloaded from Play Store on mobile or Tab.

  1. Download KPRISM app by KFin Tech.
  2. Select IPO Status (No need to do login or register to check IPO allotment)
  3. Select Glenmark Life Sciences IPO from the list.
  4. Enter Application Number or DPID Client ID or PAN, then Submit.
  5. The allotment status of Glenmark Life Sciences IPO, with no. of shares allotted will come.

Glenmark Life Sciences IPO subscription status details:

QIB (Qualified Institl. Bidders)NIB (Non-institutional Investor)RII (Retail Individual Investor)Employee categoryTotal No. of times applied
No. of shares offered     
Day 1     
Day 2     
Day 3     
Glenmark Life Sciences IPO subscription status live

Glenmark Life Sciences IPO highlights:

Glenmark Life Sciences IPO bid Opens on 27 July 2021, Wednesday
Glenmark Life Sciences IPO bid Closes on29 July 2021, Friday
Post issue Modification Period30-July-2021 (10.00 A.M. to 11.00 A.M.)
Cut-off time for UPI Mandate Confirmation30-July-2021 (upto 12:00 PM)
Issue type100% Book Building
Glenmark Life Sciences IPO issue size₹ 1513.60 Cr
Face value of each equity shareRs. 2
Glenmark Life Sciences IPO Price bandRs.695 to Rs.720 per share
Glenmark Life Sciences IPO market lot20 equity shares and multiples of 20
Glenmark Life Sciences IPO minimum order quantity20 equity shares
Pre IPO equity share of promoters of Glenmark Life Sciences____%
Post IPO paid-up equity share of promoters of Glenmark Life Sciences____%
QIB portion reservation in Glenmark Life Sciences IPO50 %
NIB portion reservation in Glenmark Life Sciences IPO15 %
Retail portion reservation in Glenmark Life Sciences IPO35 %
Retail individual bidder can apply in Glenmark Life Sciences IPOup to 2 lakh (200,000) – Maximum 13 Lot
Retail individual discount in Glenmark Life Sciences IPONA
Employees can apply in Glenmark Life Sciences IPOup to 5 lakh (500,000)
Employees Reservation in Glenmark Life Sciences IPONA
Employees Discount in Glenmark Life Sciences IPONA
Listing of Glenmark Life Sciences at ExchangesNSE, BSE
Fund raised from Anchor Investors in Pre-IPO of Glenmark Life SciencesNA
Registrar of Glenmark Life Sciences IPO issueKfin Technologies Private Limited
Glenmark Life Sciences IPO highlights

Glenmark Life Sciences IPO important dates regarding bidding, allotment, listing, refund etc. :

The probable dates regarding bidding, allotment, listing, refund of Glenmark Life Sciences IPO are mentioned below.

Glenmark Life Sciences IPO opens on27.07.2021
Glenmark Life Sciences IPO Closes on29.07.2021
Allotment basis date of Glenmark Life Sciences IPO03.08.2021
Money refund date of Glenmark Life Sciences IPO04.08.2021
Shares of Glenmark Life Sciences in Demat Account05.08.2021
Glenmark Life Sciences IPO listing date on NSE, BSE06.08.2021
Glenmark Life Sciences IPO important dates regarding bidding, allotment, listing, refund etc.

How much shares of Glenmark Life Sciences IPO are being offered?

Type of Issue (Fresh / OFS)No. of Equity shares offeredAmount of Equity shares
Total Issue size₹ 1513.60 Crore
Fresh Issue size₹ 1060 Crore
Offer for Sale (OFS)₹ 453.60 Crore
Employee Reservation
No. of Equity shares offered of Glenmark Life Sciences IPO

Glenmark Life Sciences financial statements details:

31.03.202131.03.202031.03.2019
(₹ million)(₹ million)(₹ million)
Total Assets19,970.7517,256.0414,753.95
Total Revenue18,859.7615,493.038,868.65
Profit After Tax3,515.813,130.981,955.92
Glenmark Life Sciences financial statements details

IPO Red Herring Prospectus (RHP) of Glenmark Life Sciences:

Click here for IPO RHP of Glenmark Life Sciences on SEBI website.

Objectives of the Glenmark Life Sciences IPO Issue: (Source – RHP)

Objects of the Fresh Offer

Our Company proposes to utilise the Net Proceeds from the Fresh Issue towards funding the following objects:

1.Payment of outstanding purchase consideration to the Promoter for the spin-off of the API business from the Promoter into our Company pursuant to the Business Purchase Agreement dated October 9, 2018

2.Funding capital expenditure requirements; and

3.General corporate purposes

Business of Glenmark Life Sciences: (Source – RHP)

We are a leading developer and manufacturer of select high value, non-commoditized active pharmaceutical ingredients (“APIs”) in  chronic  therapeutic  areas,  including  cardiovascular  disease  (“CVS”),  central  nervous  system  disease  (“CNS”),  pain management and diabetes (Source: Frost & Sullivan Report). We also manufacture and sell APIs for gastro-intestinal disorders, anti-infectives and other therapeutic areas.

Our API portfolio comprises specialized and profitable products, including niche and technically complex molecules, which we believe reflects our capability to branch into other high value products. We have strong market share in select specialized APIs such as Telmisartan (anti-hypertensive), Atovaquone (anti-parasitic), Perindopril (anti-hypertensive), Teneligliptin (diabetes), Zonisamide (CNS) and Adapalene (dermatology) (Source: Frost & Sullivan Report).

We are  also  increasingly  providing contract  development  and  manufacturing  operations(“CDMO”)  services  to  a  range of multinational and specialty pharmaceutical companies. We are a research and development (“R&D”)-driven API manufacturer, focused on undertaking dedicated R&D in our existing products and in areas where we believe there is growth potential in the future. We believe that maintaining high standards of process innovation and quality in our R&D and manufacturing operations is critical to our brand and maintenance of long-term relationships with our customers.

Go Back to – IPO Dashboard for other IPOs:

Current and Upcoming main board IPO, IPO Allotment link, IPO listing date, IPO performance

 

Kindly verify from RHP and concerned company for any clarification.

Leave a Reply

%d bloggers like this: